Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

5 Customer Reviews

  • Br J Cancer, 2018, 118(4):509-521. Fludarabine purchased from Selleck.

    ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

  • Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

    Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

  • Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  M3vFO2Z2dmO2aX;uJGF{e2G7 NVPLfFFZOjBizszN M37pblI1KGh? NF[xU4dqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=> M17JeVI2QTRyN{Gy
MV-4-11 MlnsRZBweHSxc3nzJGF{e2G7 MUWyMlUh|ryP NUP5ToFjPDhiaB?= NFflZ4RqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MmfxNlUyOTF3OEO=
THP-1 MU\BdI9xfG:|aYOgRZN{[Xl? MnP3Nk42KM7:TR?= M3fKVVQ5KGh? MlzTbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MkPpNlUyOTF3OEO=
MOLM 13 NXryNWFwSXCxcITvd4l{KEG|c3H5 MU[yMlUh|ryP NGPQ[Jk1QCCq NIrT[nBqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> M4\jWFI2OTFzNUiz
KBM3/Bu2506 MYrBdI9xfG:|aYOgRZN{[Xl? M1vY[VIvPSEQvF2= MUK0PEBp MonzbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MXWyOVEyOTV6Mx?=
Nalm-6 M{H2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF6IN88US=> NELvT2QzPTB4MUGwNS=>
Reh MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL4UllKSzVyPUOwJO69VQ>? NYXlO5ViOjVyNkGxNFE>
U2937 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jrcmlEPTB;MU[g{txO MXeyOVA3OTFyMR?=
Mec-1 M3f5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|Ux97zgNUCwJO69VQ>? NV;p[HlxOjVyNkGxNFE>
RPMI-8226 MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVyMDFOwG0> M{nHR|I2ODZzMUCx
Molt-4 NIDxZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG1XlVzUUN3ME2xPFAh|ryP MnLwNlUxPjFzMEG=
Nalm-6-FluR NUTScJlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvlTWM2OD1{NUCg{txO M4G2W|I2ODZzMUCx
Raji  NXXNPYV4TnWwY4Tpc44hSXO|YYm= MoezN:Kh|ryP Mn3iNlQwPDhxN{KgbC=> NY\yZYN4cW6mdXPld{Bi[2O3bYXsZZRqd26|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=> NHrTXWozPDl2ME[5OS=>
PBMC MX3GeY5kfGmxbjDBd5NigQ>? NXPvOlBRPTBxMUCwJO69VQ>? MYSyOEBp Mo\sSG1UVw>? MYjpcohq[mm2czDTWGFVOSCyaH;zdIhwenmuYYTpc44> NH3nUYozPDlzMUi3Ni=>
MDA-231 M4LwNWZ2dmO2aX;uJGF{e2G7 M4PoXlExOCEQvF2= M1HZR|I1KGh? NGHVXHRFVVOR NGnFSnll\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36= NYHtRZVoOjR7MUG4O|I>
624.38mel  M4H4SmZ2dmO2aX;uJGF{e2G7 MmLvOVAh|ryP NG[xS3gzPCCq M1:zbmROW09? NYK1NXVs\GWlcnXhd4V{KEmGTzDlfJBz\XO|aX;u MUmyOFkyOTh5Mh?=
MDA-231 M37wcWZ2dmO2aX;uJGF{e2G7 NV\zeVllPTBvMkCwJO69VQ>? NUC5OXlGOjRiaB?= MX;EUXNQ MWjpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? NW\5NIhrOjR7MUG4O|I>
624.38mel  M1;TdmZ2dmO2aX;uJGF{e2G7 M1\mVlUxNTJyMDFOwG0> MljzNlQhcA>? M{HDb2ROW09? NV7YeXZqcW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO= MoP0NlQ6OTF6N{K=
HMECs MmDDSpVv[3Srb36gRZN{[Xl? MYKxNFDDqM7:TdMg NWL1[49UOzcEoHi= NGHGOmpqdmirYnn0d{BKTk8Qs9MgZY5lKEySUzDpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSWLGNUBmgHC{ZYPzbY9v NELUTYkzPDJzMUOyOy=>
HMECs  NEfDXnFHfW6ldHnvckBCe3OjeR?= M4nlblExOMLizszNxsA> MUizOuKhcA>? NI\zRnNqdmirYnn0d{BKTk8QsdMgcYVlcWG2ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIHHu[EBUXEGWMzygZpV1KG6xdDDv[kBUXEGWMh?= NHniUFczPDJzMUOyOy=>
BJAB M4SybGFxd3C2b4Ppd{BCe3OjeR?= MX:1xsDPxE1? MYmyOEBp NFu2UGRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3LxOlI1ODV5MUS3
I-83 NVvidIdYSXCxcITvd4l{KEG|c3H5 MXi1xsDPxE1? MkTyNlQhcA>? NUT2R45wcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlHWNlQxPTdzNEe=
NALM6 MXzBdI9xfG:|aYOgRZN{[Xl? NYfidHN7PcLizszN M4DNTVI1KGh? MmmybY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1zJOlI1ODV5MUS3
DU-145 NVvvNIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[xS454OC1zMDFOwIcwdWx? NVP6VpdMPDhiaNMg MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVmyN|c{PDhzNR?=
Nalm-6 NVftc4VFTnWwY4Tpc44hSXO|YYm= NH;MXokyOMLizszN MXixM|IwPCCq MVPpcoR2[2W|IHH1eI9xcGGpeR?= M{HWVVI{PjhzMkKz
Reh NWLWeI16TnWwY4Tpc44hSXO|YYm= M4C3dFExyqEQvF2= M1XZW|EwOi92IHi= MnjrbY5lfWOnczDheZRweGijZ4m= MkfhNlM3QDF{MkO=
Nalm-6 NUe5SVVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HZUmlEPTBi4pk8NVDjiIoQvF2= NUTlPGZHOjN4OEGyNlM>
Reh MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3YTWM2OCEkiMyxNQKBkc7:TR?= MlL1NlM3QDF{MkO=
HEC1A NGP6SWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDQNVAxNTVyMDFOwG0> Mne4NlQhcA>? M3zQNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NF\FXWMzOzV7NU[5Oy=>
AN3CA NHrjRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknWNVAxNTVyMDFOwG0> MU[yOEBp NU\MdmMzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIjYW4YzOzV7NU[5Oy=>
HEC50B NILG[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHy4WZUyODBvNUCwJO69VQ>? MYSyOEBp M{n2eIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 M2TKdFI{PTl3Nkm3
HEC1A M{\1bGFxd3C2b4Ppd{BCe3OjeR?= MWiyNE8yODBizszN NF7kNGMzPCCq Ml21bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXTaPINIOjN3OUW2PVc>
AN3CA NFm4d4FCeG:ydH;zbZMhSXO|YYm= M1PaUFIxNzFyMDFOwG0> NFrnO2szPCCq NXnnN25GcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYWyN|U6PTZ7Nx?=
HEC50B M2nH[GFxd3C2b4Ppd{BCe3OjeR?= NUTJWpkyOjBxMUCwJO69VQ>? NXjSZnRsOjRiaB?= Ml;obY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NIXjU5czOzV7NU[5Oy=>
EHEB MWHBdI9xfG:|aYOgRZN{[Xl? MmrlOFAh|ryP NXPkbIs3OjRiaB?= Ml3abY5lfWOnczDhdI9xfG:|aYO= M4jpW|I{PDl5MEe1
A549 NGmzdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\4R|ZEUUN3ME2xOU44yrF{LkigxtVO MVmyN|M4PzF7Mh?=
A549 GAPDH-deficient M{nwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX2blBKSzVyPUG4MlXDuTJwMzFCuW0> MmK5NlM{PzdzOUK=
CLL  NULZd3BsSXCxcITvd4l{KEG|c3H5 Mk\JNVAh|ryPwrC= M{foUFI1NTl4IHi= NUDqTWpEcW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? M2HLR|IzOjB5Nki2
MEC1 M2THPWFxd3C2b4Ppd{BCe3OjeR?= Mn;BNVAxyqEQvF2= Mn7sO|IhcA>? MWPpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NVjSZW9KOjJzM{K5O|M>
U937  NX;DPYpySXCxcITvd4l{KEG|c3H5 MYWwMlgh|ryP MnPFOE01QCCq MV3pcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= Mnj1NlIxPzR5MEC=
U937  MU\BdI9xfG:|aYOgRZN{[Xl? M2KxbVEh|ryP NEDoNWY6PiCq Ml71bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NX7YUHQ{OjJyMkO1NlM>
Daudi M3LIZmFxd3C2b4Ppd{BCe3OjeR?= NGLJW|IzOCEQvF2= NEjhbo06PiCq M2DuNIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MlXhNlIxOjN3MkO=
J45.01 NUmzPJlJSXCxcITvd4l{KEG|c3H5 NVXafJRTOSEQvF2= NHL1NHA6PiCq MYLpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NYfrRm97OjJyMkO1NlM>
RPMI 8226 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPSTWM2OD1{NT65xsDDucLiMz63JO69VQ>? M13PSlIyQTR6Mk[0
CEM NF[xVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK3e5hxUUN3ME2yMlTDqMLzwrCwMlQh|ryP NWC0Zms{OjF7NEiyOlQ>
Raji M3vv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PjbmlEPTB;MD60O:KhyrIEoECuNFQh|ryP MX2yNVk1QDJ4NB?=
U937 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PyUWlEPTB;MD6yOOKhyrIEoECuNFQh|ryP NWTLVXRLOjF7NEiyOlQ>
K562 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL0TY57UUN3ME2wMlQ1yqEEsdMgNE4xPSEQvF2= NUXzelY{OjF7NEiyOlQ>
NALM-6 NU\hbYJISXCxcITvd4l{KEG|c3H5 MUmxNEDPxE4EoB?= MoPxNlQhcA>? MlHMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|bHnnbJRtgQ>? NX32c|FzOjF4OUmzPFM>
JMV-3 Moq1RZBweHSxc3nzJGF{e2G7 NGP5dWoyOCEQvF5CpC=> Mom0NlQhcA>? M2K4dolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? NH;aTFEzOTZ7OUO4Ny=>
EHEB NXrtcHZoTnWwY4Tpc44hSXO|YYm= NITNemY2NTVyIN88US=> MnvJNlQhcA>? Mnqx[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> NXPSOHZmOjFzNkizPVE>
JVM-2  NH;2XJJHfW6ldHnvckBCe3OjeR?= M4jwNFMxKM7:TR?= MVuyOEBp MYPk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25? NV;FW2lMOjFzNkizPVE>
KBM3/Bu2506 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|IxRTBwNkegxtVO NE[5T5UzODl|M{WwPS=>
KBM3/Bu2506 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELnNZkxNjZizszN MWGyOEBp MVXpcoNz\WG|ZYOgeIhmKGOnbHyg[pJi[3Srb36gbY4hWy2yaHHz[S=> M3m1WVIxQTN|NUC5
MDA-MB-231 NV71fmJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;xOmV5UUN3ME20MlAh|ryP MVKyNFQ1PzN7MB?=
MCF-7 NEPidGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[2VmlEPTB;MUWuNEDPxE1? NWfteVR{OjB2NEezPVA>
HLE-B3  NVrkU5RuTnWwY4Tpc44hSXO|YYm= MofPNlUh|ryP NXrMcGNbPDhiaB?= MX\icI9kc3NiSV\OMe6{6oDVaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmGTzDlfJBz\XO|aX;u M{XWOlIxPDN3MUW4
K562 NUC4fpZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPGO|IhcA>? M2nDV2lEPTB;Mz6zJI5O NV2xV5k2OjB|MEexPVg>
BW-225 NIDzZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;pbJRKSzJyPUGuN|chy5dzMPMIlljDqM7:TdMg NELSTIsyQDZ4MUO4NC=>
OH-65 NH7RO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrQXJVKSzJyPUGuN|chy5dzMPMIlljDqM7:TdMg NG\GeocyQDZ4MUO4NC=>
GR-145 M1PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XOfGlEOjB;Mj63OEDEnyBzMPMIllghKM7:TdMg NHr6ZXIyQDZ4MUO4NC=>
A549 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfxeHU6UUN{ME21MlQ5KMPZIEGw5qiTQCEQvF5CpC=> NYq4WZFkOTh4NkGzPFA>
CaSki  M2G4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofPTWMzOD1zLkO3JOOYKDFy4pkSO{DPxE4EoB?= NWOxN|RkOTh4NkGzPFA>
ZMK-1 M1fMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\BSGFzUUN{ME2xMlM4KMPZIEGw5qiTPiEQvF5CpC=> MVGxPFY3OTN6MB?=
SKW6.4 MVTBdI9xfG:|aYOgRZN{[Xl? NXvKcFE2OC5yMT2xNEDPxE1? NFiwOnEzPC92ODDo M4jMU4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NIT2PGkyQDB7MkO0NC=>
RPMI 8226 M3fwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCyOEBp MXHJR|UxRTFwNUVCpO69VQ>? NX3ae5BNOTd7N{[xPFY>
MM.1S NX\KemsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK0PEBp MUnJR|UxRTF|LkS4xsDPxE1? MXexO|k4PjF6Nh?=
MM.1R NWPiS4dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm0PEBp NYL2SlFTUUN3ME2zN{44QSEQvF2= MVOxO|k4PjF6Nh?=
U937 NU\ZRYJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTZeYZRUUN3ME2zMFIxOCEEsTC1OlAhdk1? M2ra[|E2QTNyM{[x

... Click to View More Cell Line Experimental Data

In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03710421 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma City of Hope Medical Center|National Cancer Institute (NCI) June 10 2019 Phase 1
NCT03856216 Not yet recruiting Acute Lymphoblastic Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|B Acute Lymphoblastic Leukemia|CD22 Positive|Lymphocytic Neoplasm|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) June 30 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products0

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID